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https://doi.org/10.1016/j.xcrm.2021.100280SUMMARYCase fatality among African children with severe acute malnutrition remains high.We report a 3-arm pilot trial
in 58 Ugandan children, comparing feeds targeting disordered gastrointestinal function containing cowpea
(CpF, n = 20) or inulin (InF, n = 20) with conventional feeds (ConF, n = 18). Baseline measurements of gut
permeability (lactulose:mannitol ratio 1.19 ± SD 2.00), inflammation (fecal calprotectin 539.0 mg/g, interquar-
tile range [IQR] 904.8), and satiety (plasma polypeptide YY 62.6 pmol/l, IQR 110.3) confirm gastrointestinal
dysfunction. By day 28, no differences are observable in proportion achieving weight gain >5 g/kg/day
(87%, 92%, 86%; p > 0.05), mortality (16%, 30%, 17%; p > 0.05), or edema resolution (83%, 54%, 91%;
p > 0.05) among CpF, InF, and ConF. Decreased fecal bacterial richness from day 1 (abundance-based
coverage estimator [ACE] 53.2) to day 7 (ACE 40.8) is observed only in ConF (p = 0.025).Bifidobacterium rela-
tive abundance increases from day 7 (5.8% ± 8.6%) to day 28 (10.9% ± 8.7%) in CpF (corrected p = 1.000).
Legume-enriched feeds support aspects of gut function and the microbiome. Trial registration
PACTR201805003381361.INTRODUCTION
In 2016, at least 45% of the 5.6 million child deaths globally were
directly or indirectly attributable to undernutrition.1,2 Severe
acute malnutrition (SAM) remains a frequent cause of pediatric
hospitalization in much of the developing world,3 and in Africa,
it is associated with high in-hospital mortality rates of ~20%4,5
and poor long-term outcomes.6,7 One of the most vulnerable
times is early in admission during nutrition rehabilitation, when
mortality remains high, with ~70% of in-hospital deaths occur-
ring in the first 7 days4. Nutritional (anthropometric) recoveryCell R
This is an open access article undoften poorly predicts long-term outcomes,8 including increased
risk of life-threatening events (death and/or re-hospitalization
with pneumonia or diarrhea) in the 12 months following initial
admission.7,9
Factors underpinning the outcome fromSAMare complex and
multifactorial, ultimately resulting in reduced assimilation of vital
nutrients, disruption of the normal gut microbiota, altered gut
barrier function, impaired mucosal immunity,3 and increased
risk of gram-negative bacteraemia.10,11 This has prompted
investigation into the role of the gut microbiota,12,13 gut barrier
integrity,14,15 and microbial translocation16 in SAM.eports Medicine 2, 100280, May 18, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESSIntestinal mucosal integrity and gut microbial diversity can be
restored by providing substrates and inducing fermentation in
the gastrointestinal tract (GIT).17,18 Fermentable carbohydrates
are increasingly being investigated as potential adjuncts to
improve the composition of normal gut microbes and positively
influence immunological and metabolic function of the gut.19,20
Carbohydrate that escapes digestion in the upper GIT (resistant
starch and dietary fiber) induces favorable changes in colonic
microbiota fermentation.21 This leads to the generation of
short-chain fatty acids (SCFAs), which have a positive influence
on gut integrity and nutritional health by improving energy yield,
modulation of colonic pH, production of vitamins, and stimula-
tion of gut homeostasis, including anti-pathogenic activities.22,23
However, it has been demonstrated that in children, SAM is
associated with significant relative microbiota immaturity that
is only partially ameliorated on standard nutritional rehabilitation
feeds given for at least 3 weeks.13 The study also demonstrated
immaturity of microbiota in undernourished children, which
directly correlates with the weight-for-height Z score. More
recent evidence suggests that foods targeted at microbiota re-
covery that are rich in fermentable carbohydrates have positive
effects on linear growth in children with SAM.24 Part of this diet
contained legumes. Legumes, particularly cowpeas, are
commonly consumed throughout East Africa. Cowpeas (Vigna
unguiculate) have been shown to improve the protein digestibility
corrected amino acid score (PDCAAS) of traditional African sor-
ghum foods25 and also have a high resistant starch content.26 A
number of studies have demonstrated that legumes can have a
positive effect on the microbiota (e.g., to enhance SCFA produc-
tion27 and increase probiotic bacteria28). The resistance of
starch in cowpeas to small intestinal digestive enzymes is due
to a number of factors such as the structure of the starch granule
and the entrapment of the starch in the cell.29
We hypothesized that the introduction of a legume-enriched
feed containing fermentable carbohydrates in children that
have complex SAM would provide a safe and cost-effective
means of improving outcomes by restoring gut mucosal integrity
and enhancing immunity, thereby reducing diarrhea and the risk
of systemic infection. To date, studies examining the feasibility
and effectiveness of legume-enriched feeds or diets in modu-
lating gut health and microbial composition have been limited
to community-based management of chronic or moderate acute
malnutrition.30–32 Our study investigates the use of a legume-en-
riched feed in the earliest stages of inpatient stabilization in
acutely unwell children with SAM at the highest risk of death.
Children during this stage of treatment are more likely to require
antibiotic treatment,33 which can negatively impact the gut mi-
crobiota and increase risk of diarrhea.34,35 To provide proof of
this principle in Ugandan children with SAM, we assessed the ef-
fects on intestinal permeability (urine dual sugar test), SCFA pro-
duction, gut inflammation (fecal calprotectin), gut microbiome,
endocrine measures of satiety (polypeptide YY [PYY] and
glucagon-like peptide-1 [GLP-1]), and clinical outcomes in a pilot
study in children randomized 1:1:1 to standard nutritional milk
feeds with an added source of fermentable carbohydrate: (1)
milled cowpea flour (experimental legume-based: cowpea
[Cp]-enriched feeds [F] [CpFs]), (2) inulin (In) (experimental non-
plant-based: inulin-supplemented feeds [InFs]), or (3) standard2 Cell Reports Medicine 2, 100280, May 18, 2021nutritional feeds F75 followed by F100 milk (Nutriset, France)
(control feed: ConF). Children enrolled on admission to hospital
(day 1) were followed up on days 7 and 28 post-enrollment. All
other treatments were standardized across the study group.
RESULTS
Feed development, including assessment of the impact of CpFs
on fecal microbiota in vitro (Figures 1A and 1B) and trial method-
ology, are presented in the STARMethods section. Modifying in-
testinal integrity and microbiome in malnutrition with legume-
based feeds (MIMBLE) was a single-center (Mbale Regional
Referral Hospital), open-label, proof-of-principle randomized
comparator trial evaluating safety and feasibility of three feeding
strategies. Trial flow and baseline characteristics are summa-
rized in STAR Methods and Table S1. All three feeds were well
tolerated with no reported palatability problems. Mean duration
(± SD) of feeding days was 14 ± 8 for ConFs, 14 ± 9 for InFs,
and 18 ± 9 for CpFs (Figure 1C). There was no difference in
adverse event rates, which were all judged to be causally unre-
lated to intervention.
Anthropometric recovery and mortality across the
cohort
The primary endpoint of nutritional rehabilitation (moderate
weight gain > 5 g/kg/day36) was achieved in most children (37/
42; 88%), with no difference among intervention arms. The co-
primary endpoint was 28-day mortality, which, overall, remained
high (21%), with no difference among arms (p value for log-rank
test: p = 0.48; Figure 1D). Duration of hospital stay did not vary
significantly among the intervention arms: ConF median stay
was 15.5 days (interquartile range [IQR] 11.0), InF median stay
was 10.5 days (IQR 17.0), and CpF median stay 20.0 days (IQR
14.0) (Kruskal-Wallis test, p = 0.183).
Baseline physiological measures and relationship to
mortality
Baseline characteristics were relatively similar across the three
arms with some imbalances (more diarrhea/dehydration in the
CP group). Overall, children that died (versus survivors) had a
lower fecal gut microbiota diversity (Figure 2A). We found a sig-
nificant difference at phylum level, with high levels of Proteobac-
teria in those children that died (relative abundance 52.5%; SD
11.6) compared to those who survived (37.9%; SD 22.8; Benja-
mini-Hochberg false discovery rate [FDR]-corrected p = 0.04)
(Figure 2B). Proteobacteria are a large class of bacteria that
include a number of pathogens (Salmonella enterica, Pseudo-
monas xanthomarina, Hafania alvei, Klebsiella pneumoniae, and
Escherichia coli) and that have been shown to be enriched in chil-
dren with severe undernutrition.37 In the current study, these
species were not identified, and the significant differences ex-
isted at the phylum and family levels only. At the family level,
there was significantly higher levels of Enterobacteriaceae in
the stool of children that died (51.9%; SD 10.1) compared to
those who survived (36.5%; SD 23.4; Benjamini-Hochberg
FDR-corrected p = 0.046) (Figure 2C). Despite a similar microbial
diversity, the children that did not recover had significantly lower
fecal propionate and butyrate (Figures 2D and 2E), suggesting a
Figure 1. Pre-clinical study in vitro batch culture: microbiota for the three feeds, days exposed to nutritional treatment, and co-primary
endpoint (survival)
(A and B) Total bacteria and Bifidobacteria following the batch culture experiment performed in triplicate.
(C) Number of days children received nutritional feeds/treatment by arm (SD). ConF, n = 18; InF, n = 20; CpF, n = 20.
(D) Primary and secondary outcomes; data for weight gain to day 28 are reported for survivors to this time point.
Additional characteristics are summarized in Table S1.
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OPEN ACCESSlower functionality of the microbiota. These are two SCFAs that
play an important role in colonic health.38,39 Specifically, buty-
rate is important as an energy source for colonocytes and for
maintaining epithelial integrity.40 Although all SCFAs cause
smooth muscle relaxation and vasodilation, propionate seems
to have a specific effect on mesenteric small arteries enhancing
blood flow to the colon, which is critically important in maintain-
ing oxygen to a highly metabolic tissue.41
When assessed at baseline, the urinary lactose:mannitol (L:M)
ratio was significantly higher (p = 0.002) in those children who
subsequently died (6.6 IQR [6.4]) within 28 days compared with
those children who survived (0.2 IQR [0.5]) (Figure 2H), suggest-
ing that the children who died had impaired mucosal intestinal
function and increased gut permeability. These results are
similar to those previously reported in a systematic review by
Denno and colleagues.42 Similarly, urinary %L was significantly
higher (p = 0.004) in children who subsequently died (0.4 IQR
[1.6]) over the 28 days of follow up compared with those children
who survived (0.1 IQR [0.3]). There was no difference in urinary%
M at baseline between those children who survived and those
who died.
Wemeasured the anorectic gut hormone PYY to understand a
driver of appetite regulation. The gut hormone PYY was signifi-cantly higher at baseline in those that died (Figure 2I), an obser-
vation that points to intestinal dysfunction.43 In a survival
analysis, higher baseline PYY was significantly associated with
mortality in the whole cohort (Hazard Ratio]HR] = 2.2 [95% con-
fidence interval (CI) 1.4-3.4], p = 0.0005; Figure 2I). In a Cox pro-
portional hazards model containing age, sex, feed intervention,
pediatric emergency triage (PET) score, and baseline PYY, only
PYY was significantly associated with mortality (adjusted HR =
2.8 [CI 1.6–5.1]; p = 0.0004) (Table S2). Overall, these results
demonstrate that the gut is highly dysfunctional in children who
die, with potential increases in pathogenic bacteria and low
levels of butyrate. The impairment of gut-barrier integrity
(increased L:M ratio) and a greater increase in the anorectic hor-
mone PYY suggest a pathophysiological connection between in-
testinal dysfunction and mortality.
Changes in GIT health over time on standard nutritional
feeds
The World Health Organization (WHO) standard feeding group
(ConF) offered the opportunity to investigate the impact of the
WHO standard nutritional therapy program over a 28-day follow
up onGIT health. The fecal microbiota diversity showed very little
change over the 28-day intervention or change in major phylaCell Reports Medicine 2, 100280, May 18, 2021 3
Figure 2. Baseline parameters of children with respect to outcome (death versus survival) for all children irrespective of intervention arm
(A–D) Baseline diversity of the microbiota by outcome (A), phylum (B), class (C), and family level (D). Benjamini-Hochberg FDR-corrected p values are shown. n =
53 (died n = 10/survived n = 43).
(E–G) Fecal SCFAs. (E) n = 33 (n = 4 died, n = 29 survived); (F) n = 45 (n = 8 died, n = 37 survived); (G) n = 35 (n = 5 died, n = 30 survived).
(H) Urinary L:M ratio. n = 37 (n = 7 died, n = 30 survived).
(I) Plasma concentrations of PYY (peptide tyrosine tyrosine) at baseline. n = 54 (n = 12 died, n = 42 survived).
(J) Kaplan-Meier plots for the quartiles of plasma PYY and survival status. n = 54
Results are presented as medians with 95% confidence limits (CLs). Comparisons between intervention arms are made by Kruskal-Wallis one-way analysis of
variance and Mann-Whitney U test. Baseline fecal samples were available for 53/58 children only, hence the results reported above for diversity (A), bacterial
phyla (B), classes (C), and families (D) and fecal SCFAs are reported for available samples only. Sample numbers vary due to sample availability. Additional Cox
proportional hazards models are reported in Table S2.
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Malawian twin study, where there was no change in the micro-
biota of children with kwashiorkor when exposed to ready-to-
use feeds.44 However, we do show change at the phylum level,
with high percentages of Proteobacteria on days 1 and 7
compared to day 28 (Figure 3B). This phylum is very diverse
but contains the Gammaproteobacteria class, which was in
particularly high density in children who subsequently died.
Enrichment of Proteobacteria has previously been reported in
children with SAM, more specifically in those with the kwashi-
orkor phenotype.37 The reduction in Firmicutes and Bacteroi-
detes is of interest, as these two saccharolytic phyla are respon-
sible for SCFA production.45 Here, we report that fecal SCFA
concentrations on admission to hospital were approximately
one-third of the concentration of those reported in healthy Afri-
can infants.46 There are different sampling and analytical
methods used to determine fecal SCFAs in healthy children in
this study, allowing for some comparison. Ideally, in the future,
it will be necessary to derive normative data using the same4 Cell Reports Medicine 2, 100280, May 18, 2021method. However, there was a suppression of the SCFAs propi-
onate and butyrate at day 7 (to about one-tenth of the normal
concentrations) that recovered by day 28 (Figure 3C). We sus-
pect that the suppression of SCFAs at day 7 may have been
due to the use of antibiotics,47 which recovered once antibiotic
treatments were stopped. Antibiotic treatments given in this
study are summarized in Table S4; no difference was observed
in the types used among the intervention arms.
On day 1, fecal calprotectin was high (median 539 mg/g stool;
IQR: 904.75) and similar among the three intervention arms.
There was a stepwise decrease in fecal calprotectin over time,
when comparing day 1 versus day 7 (p = 0.049) and day 1 versus
day 28 (p = 0.0068, adjusted for multiple comparisons) (Fig-
ure 3D). Similar trends were also seen for PYY (Figure 3E), sug-
gesting that GIT is improving in all intervention arms over time.
No significant change was observed in urinary median
mannitol excretion, but lactulose excretion increased signifi-
cantly on day 7 (median: 0.94%; lactulose-recovered IQR:
0.99) compared with day 1 (median: 0.21%; lactulose-recovered
Figure 3. Changes over three time points (day 1, day 7, and day 28) of gut function markers in children receiving ConF (n = 18)
(A and B) Admission 16S rRNA-derived bacterial phyla relative abundances for F75 control arm at each time point demonstratingProteobacteria are higher in days
1 and 7 than in day 28. Firmicutes are higher in day 28 than in days 1 and 7, andBacteroidetes are higher in day 28 than in day 7. Day 1, n = 16; day 7, n = 13; day 28,
n = 13.
(C) Fecal SCFA concentrations. Days 1/7/28: acetate, n = 13/13/13; propionate, n = 13/13/13; butyrate, n = 13/13/13.
(D) Fecal calprotectin. Days 1/7/28: n = 13/13/13.
(E) Plasma PYY. Days 1/7/28: n = 17/15/14.
(F) L:M ratio. Days 1/7/28: n = 7/7/7.
(G) OPLS-DA (Orthogonal Projection to Latent structures-Discriminant Analysis) scores and loading plots of plasma 1H NMR spectra showing differentiation in
metabolite profiles of day 1 to day 7. Days 1/7: n = 14/14.
Comparisons between days were made by t test or ANOVA where relevant.
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OPEN ACCESSIQR: 0.24, p = 0.002) before falling again on day 28 (median:
0.41%; lactulose-recovered IQR: 0.53). Our interpretation of
these results is that antibiotics initiated on admission decreased
colonic microbial diversity, leading to a decrease in SCFA pro-
duction.48,49 SFCAs, particularly butyrate, are important in the
maintenance of the colonic epithelium. Low concentrations will
lead to a decrease in epithelial integrity and an increase in lactu-
lose absorption and excretion on day 7. From days 7 to 28,
following the completion of antibiotic treatment, microbial
SCFA production increased, resulting in a stimulation of animproved epithelial integrity and a decrease of lactulose absorp-
tion and excretion. No significant change was observed in the
L:M ratio (Figure 3F). These results show that even in SAM chil-
dren who survive, there is significant GI dysfunction on admis-
sion (high fecal calprotectin and raised L:M ratio), which
improved over the 28 days. It is of interest that there was a
decrease in SCFA concentrations on day 7, following the
commencement of antibiotic therapy.
The plasma metabolomic enquiry demonstrated that there
was good separation between days 1 and 7 in the metaboliteCell Reports Medicine 2, 100280, May 18, 2021 5
Article
ll
OPEN ACCESSprofile, driven primarily by glucose elevation at day 1 and a rela-
tive increase in lipid by day 7, reflecting either dietary changes or
the effect of sepsis and subsequent recovery (Figure 3G). Addi-
tionally, trimethylamine (TMA)-N-oxide (TMAO) was high on
admission. TMAO is produced in the liver from TMA, a gut
metabolite associated with Proteobacteria, which is also high
on days 1 and 7.50 TMAO is of interest, as it has been associated
with a negative effect on muscle and linear growth.51
Impact of CpFs on gut health in comparison to ConFs
and InFs
In themeasures of intestinal injury and integrity, therewas no sig-
nificant difference in fecal calprotectin (Figure 4A) among the
three feeds. Although the dual-sugar test demonstrated a
significant effect of time for urinary mannitol excretion (%M,
p = 0.0001) (Figure 4B), there was no effect of intervention (p =
0.12) or a significant intervention 3 time interaction (p = 0.32).
There was a significant intervention effect for urinary lactulose
excretion (%L, p = 0.024) but no effect of time (p = 0.27) or a sig-
nificant intervention 3 time interaction (p = 0.44). There was a
significant time effect (L:M, p = 0.006) on the urinary L:M ratio,
but there was no effect of intervention (p = 0.18), and there
was a trend toward a significant intervention 3 time interaction
(p = 0.063) (Figure 4B). Likewise, there were no significant differ-
ences among intervention arms for the gut hormones GLP-1 and
PYY (Figure 4C). SCFA (Figure 4D) analysis found few differ-
ences among intervention arms for acetate. Butyrate showed a
significant decrease at day 7, followed by recovery at day 28
to the level observed at day 1 in the ConF group, while a similar
pattern was found for propionate in inulin-treated patients. In
contrast, in cowpea-treated patients, this decline was truncated,
with no significant changes over time (Figure 4D). We used a
commercial source of inulin, a fructan, as a standard non-digest-
ible fermentable carbohydrate to enrich the feeds in one arm
(InF). However, we did not observe the same effect as CpFs on
SCFAs or amelioration of the reduction in microbial diversity at
day 7 with InF, suggesting that digestion/fermentation of this
substrate may have been limited (Figure 4D; Table S3). Similar
observations have been made with manufactured resistant
starches (e.g., hylon, a high-amylose starch derived from
maize,52 results in significant excretion in stool). This may also
explain hylon’s limited effect when used in malnourished Mala-
wian children.53
Analysis of the microbiome demonstrated a significant
decrease in microbial richness as calculated by ACE (abun-
dance-based coverage estimator) in the ConF group (day 1
ACE = 55.5 ± SD 20.9; day 7 ACE = 42.2 ± SD 12.9; post-hoc Tu-
key p = 0.027). A similar but insignificant drop in ACE occurred in
the InF group (day 1 ACE = 57.2 ± SD 32.3; day 7 ACE = 35.4 ±
SD 12.7; post-hoc Tukey p = 0.108) (Figure 4E; Tables S3 and
S4). In the CpF group, the drop in richness from day 1 (ACE =
56.0 ±SD 31.0) to day 7 (ACE = 47.9 ±SD 20.6) was less extreme
and statistically insignificant (p = 0.691). No significant differ-
ences were observed in Bifidobacterium genus relative abun-
dance either over time or among intervention arms (Figure 4F),
although by day 28, the CpF group had the highest relative abun-
dance (10.9% ± SD 8.7%) of the three intervention arms (ConF =
8.9% ± SD 10.3%; InF = 5.7% ± SD 5.8%; Kruskal Wallis H-test6 Cell Reports Medicine 2, 100280, May 18, 2021BH FDR (Benjamini-Hochberg False Discovery Rate method) p =
1.000).
Taken together, these results suggest that the CpF has a pos-
itive effect on the fecal microbiota, particularly between days 1
and 7. This is of particular interest, given that antibiotics are
started over this period of time. Antibiotic usage is reported in
Table S5; however, the only difference observed was that no
children in the ConF group received four separate antibiotics,
compared to 25% (n = 5/20) of children in the InF arm and
20% (n = 4/20) of children in the CpF arm (p = 0.023) received
4 antibiotics. It also appears that the microbiota functionality
may be protected by the CpF with no fall in butyrate.
DISCUSSION
This study adds to the number of reports of undernourished
children that have demonstrated a relatively immature fecal
microbiota with low microbial diversity,54,55 leading to produc-
tion of lower concentrations of SCFAs, which are critically impor-
tant to epithelial function and integrity. We suspect that the use
of antibiotics results in a further lowering of microbial diversity,
resulting in lower SCFA concentrations at a critical period of
nutritional rehabilitation: in the first week, when mortality rate is
highest. Lower levels of stool butyrate and propionate have
been observed in children who died from SAM compared to sur-
vivors.15 This observation is shown in the present study, where
the children who died had significantly lower stool concentra-
tions of butyrate and propionate than those that survived. Even
at day 28, the microbiota diversity was as low as admission,
and SCFA concentrations had only recovered to admission
concentrations.
In children that died, compared to those that survived, there
appeared to be increased levels of gut dysfunction including
increased fecal proteolytic bacteria on admission and day 7,
together with a significantly higher L:M ratio, suggesting a loss
of gut integrity. We also observed that the gut hormone PYY
was significantly higher in those that died,56 suggesting appetite
dysregulation. Gut integrity has been shown by others to be
related to mortality.57 Although not fully understood, this may
be due in part to a low diversity of microbiota in which pathogens
can flourish, resulting in increased risk of toxins and enteric bac-
terial pathogens crossing the perturbed gut barrier. This is likely
to result in an increased risk of gram-negative sepsis,4,10 as sup-
ported by the reduction in gut integrity assessed by the L:M ratio.
It is of interest that children who received the ConF had low
bacteria diversity on admission, specifically with low levels of
saccharolytic bacteria (Firmicutes and Bacteroidetes) that relate
to the low concentration of fecal SCFAs, which relates to a
marker of gut dysfunction. We believe these findings early in
admission are further compounded by the routine use of antibi-
otics. A significantly greater proportion of children in the InF
(25%, n = 5/20) and CpF (20%, n = 4/20) received four antibiotics
during their inpatient admission, compared to the ConF group
(0%, n = 0.18; p = 0.023) (Table S5).While durations and dosages
could not be examined methodically, the fact that higher fecal
SCFA concentrations and lower L:M recovery and ratios were
found in children in the CpF group at day 7 is encouraging. These
differences support the hypothesis that provision of a
Figure 4. Differences among the three intervention arms over time (days 1, 7, and 28) on markers of gut function
(A) Fecal calprotectin. ConF/InF/CpF: day 1, n = 13/10/15; day 7, n = 13/15/15; day 28, n = 13/10/15.
(B) Mannitol lactulose test. ConF/InF/CpF: day 1, n = 7/5/10; day 7, n = 7/5/10; day 28, n = 7/5/10.
(C) Fasting PYY and GLP-1. ConF/InF/CpF: day 1, n = 17/18/19; day 7, n = 15/12/15; day 28, n = 14/9/14.
(D) Fecal SCFAs. ConF/InF/CpF: day 1, n = 13/15/17; day 7, n = 13/13/15; day 28, n = 13/10/15.
(E) ACE (abundance-based coverage estimator) assessment of fecal bacterial richness. ConF/InF/CpF: day 1, n = 16/19/18; day 7, n = 13/13/15; day 28, n = 13/
10/15.
(F) Bifidobacterium relative abundance. Data are presented as median with 95% CL. ConF/InF/CpF: day 1, n = 13/18/17; day 7, n = 13/13/15; day 28, n = 13/10/
15.
Comparison between and within intervention arms was carried out using Kruskal-Wallis one-way analysis of variance. Full experimental results are reported in
Tables S3 and S4.






OPEN ACCESSfermentable carbohydrate source helps preserve bacterial func-
tionality in the face of antibiotic use.
The current study has evaluated the use of a legume-enriched
feed instituted from admission in children hospitalized with se-
vere and complicated malnutrition. We used cowpeas as the
supplement to ConF support, as these were locally grown and
are a general part of standard diets.58 In our proof-of-concept
study, we demonstrated no adverse effects of the feed, which
has resulted in a phase II trial using a food industry standard
feed developed by a commercial partner.59 The children ran-
domized to the CpF gain a similar amount of weight, had
increased mid-upper arm circumference, and had no difference
in diarrheal episodes compare to ConFs. In fact, our data indi-
cated legume-enriched feeds reduced the impact of antibiotics
on further lowering the diversity of the microbiota early in the
course of admission/nutritional rehabilitation. Legume-enriched
feeds have been used in stable stunted children in the past
and are shown to have a positive effect on growth faltering32
and gut integrity.30 Further research is warranted.Limitations of study
The current study is a proof-of-principle trial assessing safety
and tolerability of a legume-enriched feeds, compared to ConFs.
No formal sample size calculation was possible due to a lack of
previous studies reporting on the physiological measures
included, such as gut hormones, fecal SCFAs, plasma 1H NMR
metabolic profiles, and gut microbial profiles. While weight re-
gain could have been chosen, weight as a clinical outcome has
little relation to the physiological markers used to assess the
wider effect of feeds. The study was limited in duration to
28 days, so longer-term outcomes of children are not available,
which may affect some of the conclusions of this study.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Data and code availability
The datasets generated during this study are available at Mendeley Data (https://data.mendeley.com/datasets/2w9kjrb682/2).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Development of cowpea enriched feed
Our aim was to source a locally grown legume rich in fermentable carbohydrate, milled into a flour that could be used to supplement
standard undernutrition recovery feeds F75 and F100 (detailed recipes outlined in supplementary information) to supply 0.5 g of resis-
tant starch/100ml similar to that gained from fermentable oligosaccharide content of breast milk.60 First, we investigated the impact
of cowpea flour and cowpea flour enriched feed on faecal microbiota in-vitro as described in Olano-Martin et al.61 To do this we un-
dertook batch culture investigation (Figures 1A and 1B). Briefly, 10% faecal slurry was prepared, 10% of which was inoculated into
the fermenter alongside ConF, InF and CpF feeds and inulin/cowpea flour separately for 1% final concentration. This was run in trip-
licate with 3 different faecal donors (who had not had antibiotics for at least 6months prior to the donation). Samples were fixed in 4%
paraformaldehyde, then washed with phosphate-buffered saline (PBS), then stored in 1:1 PBS/ethanol in 20. Total bacteria was
determined by fluorescence in situ hybridization. We found an increase in microbial number and Bifidobacteria, which are thought
to have a beneficial impact on health, when milled cowpea and cowpea supplemented feed was added to the batch culture.
Human subjects
Trial design
Modifying Intestinal Integrity and Microbiome in Malnutrition with Legume-Based Feeds [MIMBLE] was a single center (Mbale
Regional Referral Hospital) open-label, proof-of-principle randomized comparator trial evaluating safety and feasibility of three
feeding strategies. Between 25th January and 26th April 2016 we screened 69 children and enrolled 58 children within 24 hours of
hospital admission following informed consent and followed for 28 days (Figure S1). A formal sample size calculation was not con-
ducted but 20 patients per feeding strategy were felt to provide sufficient numbers to assess safety and preliminary data on phys-
iological measurement. The co-primary outcome was weight gain (moderate to good: > 5g/kg/day) and survival to Day 28. Clinical
secondary outcomes included time to diarrhea resolution (if > 3 loose stools/day), edema resolution and nutritional rehabilitation.
Physiological endpoints included changes in intestinal biomarkers: (i)Intestinal permeability (dual sugar test), intestinal cell injury
(faecal calprotectin) (ii) Microbiota:% change in gut microbial flora (iii) Metabolomics: changes in generation of short chain fatty acids
and host and microbiota metabolic products and (iv) Gut hormone profile: change in response to feed.
Patient eligibility
Children were eligible for inclusion if they were aged > 6 months < 60months (5years) and had one or more signs of severe acute
malnutrition (mid-upper arm circumference (MUAC) < 11.5cm, weight-for-height Z-score (WHZ) <3 or kwashiorkor (bilateral pedal
to generalized edema).36 Critically sick children with severe malnutrition complicated by impaired consciousness, shock, severe
dehydration or infants exclusively breastfed were excluded from the trial. Baseline characteristics are summarized in Table S1.
The protocol was approved by the ethics committees of Imperial College London (15IC3006) and Mbale Regional Referral Hospital
(UG-IRC-012). The trial was conducted to the standards of ICH Good Clinical Practice.
METHOD DETAILS
Clinical trial
Trial medication: Feed preparation
All nutritional feeds were prepared every 12 hours and stored in a refrigerator (2-8C) until use. F75/F100 were prepared according to
packet instructions with sterile water as described in the following link: https://motherchildnutrition.org/malnutrition-management/
info/feeding-formulas-f75-f100.html (accessed May 2020). For InF, a commercial source of mixed chain length inulin (2-60, Orafti
Synergy1, BENEOGmbH,MannheimGermany), was added to F75/F100 packet formulations at 4.8g per liter. CpFwasmade by add-
ing 35 g/liter cowpea flour to defined amounts of full cream milk powder, sugar, water and vegetable oil to represent F75/F100. The
mixture was simmered for 30 minutes. Once cool 20mls/liter mineral mix was added.
Trial procedures and blinding
Fifty-eight children were randomized on a 1:1:1 ratio to WHO nutritional recovery feeds (F75 followed by F100 milk (Nutriset, France)
as standard control feeds (ConF n = 18) against standard nutritional feeds enriched with cowpea flour (CpF n = 20) and standard
recovery feeds with added standard volume of inulin as positive fermentable carbohydrate control (InF n = 20). Children were fed
3-hourly at a set volume based on their weight, type of malnutrition (non-oedematous versus oedematous) and stage of nutritional
rehabilitation as per standard WHO in-hospital SAM management. Feeds were observed by study staff and any balance remaining
was recorded for compliance monitoring. All other indicated treatments, including routine antimicrobial therapy, were provided and
were the same across all intervention arms. Nurses/doctors were unblinded; all laboratory investigations were assayed blinded.Cell Reports Medicine 2, 100280, May 18, 2021 e2
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and anthropometric measurements were balanced between intervention arms, with 37 (64%) children overall presenting with edem-
atous malnutrition. A significantly higher prevalence of diarrhea on trial admission in those randomized to cowpea milk feeds (9/19
(47%) versus 4/38 (11%) in other intervention arms) precluded the use of its resolution as secondary endpoint.
Clinical monitoring
Weight, MUAC and edema score were recorded daily during admission and at day 28. Clinical observations were recorded at set
time-points. On admission to day 2, these comprised of 8 hourly pulse rate, respiratory rate, oxygen saturations, axillary temperature,
blood glucose (except day 2 when only two measurements were taken) and a standardized questionnaire detailing clinical condition.
From day 3 onward observations became 12 hourly pulse rate, respiratory rate, oxygen saturations, axillary temperature and ques-
tions on clinical condition. Antibiotic treatments that were received are summarized in Table S5.
Sample collection and lactulose: Mannitol (dual sugar) test
On admission/day 1, 7 and 28 plasma (for gut hormones, metabolomics (with matched urine samples)) and stools (for faecal calpro-
tectin, SCFAs and 16S rRNA analysis) were collected, aliquoted and stored at80C. On days 1,7 and 28 children received 2ml/kg of
L:M solution (containing 250mg/ml lactulose and 50mg/ml mannitol (stored 2C8C)). Urine was collected in a urine collection bag
for one hour prior to L:M solution administration (pre-LM urine sample). L:M solution administration was immediately followed by a
feed. Participants then fasted for 5 hours (blood glucose monitored during this period) and all urine passed during this time was
collected in a urine collection bag at each void (post-LM urine samples). Urine was immediately stored at 80C. Simultaneously
the gut hormones (PYY and GLP-1) pre-feed plasma sample was obtained approximately 15 minutes prior to the end of the 5
hour fast and the post-feed sample approximately 1.5 hours after feed completion. Post-LM urine samples were homogenized at
a later date which involved one freeze-thaw cycle, vortexing for 30 seconds to ensure mixing, centrifuging at 400 g for 5 minutes
and then aliquoting into two 2ml samples to be stored at 80C. Plasma was extracted from blood samples and stored at 80C.
All samples were transferred to Imperial College for further analysis.
Urine aliquots were transferred to SUERC, University of Glasgow for LM analysis. Using a modified anion exchange chromatog-
raphy coupled with pulsed amperometry detection (ThermorFisher Scientific Dionex ICS3000 with CarboPac PA20 Analytical (3 3
150 mm), Eluent Gradient: 10 mM OH from 7 to 1 min, 10–30 mM KOH from 1–9 min, 30–35 mM KOH from 9–16 min, Flow
Rate: 0.5 mL/min, pulsed amperometric, disposable Au on PTFE electrode (carbohydrate 4-Potential Waveform));62 lactulose and
mannitol were quantified using a combination of internal and external standard calibration. Briefly, internal standard (cellobiose,
20 mM, 50 uL) was added to 1 mL thawed urine. An aliquot of this stock urine (60 mL) was diluted with ultrapure water to 1500 mL
total volume and 50 mg of mixed-bed ion exchange resin (Sigma-Aldrich, Gillingham, UK) added to remove interfering ions. Finally,
samples were spun (400 x g) and the supernatant decanted to a clean vial for analysis. Concomitantly, the same internal standard
was added to a set of external standards containing lactulose and mannitol (six-level calibration, range 0-5mM). Urine sample
lactulose:cellobiose and mannitol:cellobiose area ratio was used against the external standard curve lactulose:cellobiose and
mannitol:cellobiose area ratio (blank corrected mannitol R2 = 0.998 and lactulose R2 = 0.992) to calculate %L, %M and L:M using
individual sugar dose and appropriate dilution corrections.
Faecal calprotectin
Faecal Calprotectin was measured using a standard by standard enzyme-linked immunosorbent assay (Charing Cross Hospital, Im-
perial College Healthcare NHS Trust, London). Only participants completing the study with three time points or day 0/1 and day 28
were analyzed.
Gut hormones
Plasma PYY63 and GLP-164 were measured using a sensitive and specific in-house radio immunoassay at Imperial College, London
Gas chromatography-mass spectrometry
Stool short chain fatty acid SCFA (propionate, butyrate and acetic acid) concentrations were analyzed using a gas chromatography
system Agilent 7890A GC (Agilent Technologies, Palo Alto, CA, USA) fitted with a high polarity, polyethylene glycol, fused silica
capillary column DB-WAXetr ((30 m, 0.25 mm id, 0.25 mm m film thickness) Agilent Technologies 122-7332LTM). The GC system
was coupled to a mass spectrometer system Agilent 5977A, single quadrupole detector with an EI source at 70 eV. Scanning the
30–250 m/z range. The ion source temperature was 230C, single quadrupole temperature was 150C and transfer line temperature
was 280C. A solvent delay of 3.5 min was used. The target ions of the single ion monitoring (SIM) employed for this method were:
acetic acid-60 m/z, propionic acid-74 m/z and butyric acid- 73 m/z. Identification of the SCFAs was based on the retention time of
standard compounds. Stool samples were processed according to published methods.65
Proton (1H) nuclear magnetic resonance (NMR) spectroscopy
The methods for sample preparation for NMR spectroscopy have been previously described.66 Plasma buffer (0.075M NaH2PO4)
was prepared as follows and stored at 4C: 5.32 g of NaH2PO4 was dissolved in 380ml of water. 0.4g of reference compound
(TSP) was added to this solution and dissolved. 5ml of 4% NaN3 solution was added and mixed, then 100ml of D2O added. pH
was adjusted to 7.4 using 1M HCl solution. The solution was transferred to a 500ml flask and volume adjusted to 500ml with water.e3 Cell Reports Medicine 2, 100280, May 18, 2021
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were added to a microcentrifuge tube that was then vortex mixed and centrifuged for 12000 g at 4C for 5 minutes. 600ml of
supernatant was transferred into a SampleJet 5mmNMR tube (Bruker, Karlsruhe Germany), then sealed with POM balls. NMR spec-
troscopy was conducted using a Bruker 600Mhz Avance Spectrometer (Bruker, Karlsruhe Germany). A 1H 1-dimensional (1D) profile
was acquired for each sample using a standard 1D pulse sequence employing the first increment of a Nuclear Overhauser Effect
pulse sequence to achieve pre-saturation of thewater resonance, followed by aCarr-Purcell-Meiboom-Gill (CPMG) sequence exper-
iment. A 2-dimensional (2D) J-res experiment was also acquired to exploit the structural properties and help with biomarker
identification.
16S rRNA sequencing
QIAamp PowerFecal DNA Kits (QIAGEN, Hilden Germany) were used for faecal DNA extraction. QIAamp PowerFecal DNA Kits (QIA-
GEN, Hilden Germany) were used to extract faecal DNA as described in the protocol. Briefly, inside a biosafety cabinet, 250mg of
defrosted faecal sample was transferred into a safe-lock microcentrifuge tube. To this glass beads were added and then 750ml of
bead solution and 60ml of solution C1. Tubes were then heated at 65C for 10minutes, and placed into the Bullet Blender Storm in-
strument (Next Advance Inc., New York USA), and bead beaten for 3 minutes at speed 8. Tubes were removed and centrifuged for
1minutes at 13,000 g, after which supernatant was transferred to a cleanmicrocentrifuge tube. 250ml of solution C2was added to the
supernatant, then vortex mixed, and incubated at 4C for 5 minutes. The tubes were then re-centrifuged at 13,000 g for 1minute, and
up to 750ml of supernatant transferred to a new tube, while avoiding the pellet. 1200ml of solution C4 was added to the supernatant
and then vortex mixed. The mixture was loaded onto a spin filter and centrifuged at 13,000 g for 1 minute in 3 3 650ml batches dis-
carding the flow through until all had been filtered. 500ml of solution C5 was then loaded onto the filter, and centrifuged at 13,000 g for
1 minute. The extracted DNAwas then eluted from the filter by adding 100ml of solution C6, and centrifuging for 1 minute at 13,000 g.
Aliquots of 25ml volume of the eluted DNA was transferred to new tubes and stored at 80C.
Prior to sequencing, the concentration of DNA was determined using Qubit dsDNA BR assay kits (Thermo Fisher Scientific, Mas-
sachusetts USA) as per the protocol, and where necessary DNA was diluted to below 5mg/ml. Sample libraries were prepared ac-
cording to Illumina’s protocol. Illumina 2017. 16S Metagenomic Sequencing Library Preparation Available: https://support.
illumina.com/downloads/16s_metagenomic_sequencing_library_preparation.html [Accessed 10/1/2017 2017]. The forward primers
(28F-YM, 28F-Borrellia, 28FChloroflex, 28F-Bifdo) were in a mix with a ratio of 4:1:1:1, and the reverse primer used was 388R.67
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
Statistical analyses were conducted using GraphPad Prism software (version 8.1.2) or R (version 3.6.2). Data are presented as mean
± standard deviation (s.d.) or median ± interquartile range (IQR), as stated. Comparisons between two groups were performed via a t
test or Mann-Whitney test, as appropriate. Faecal calprotectin, gut hormone, urine sugar and SCFA data were analyzed usingmixed-
effects models with time (day 1, 7 and 28) and treatment group (standard feed, inulin or cowpea) as fixed effects. Post hoc multiple
comparisons were done via Tukey’s test.
Survival analyses were performed in R using the ‘survival’ and ‘survminer’ packages. For 28-day mortality, Kaplan-Meier plots
were constructed according to treatment group, statistical difference between intervention arms was assessed via the log-rank
test. To assess the association between baseline PYY and 28-day mortality, Kaplan-Meier plots were first constructed according
to PYY quartile (to allow for graphical representation of the effect), with statistical difference between the quartiles assessed via
the log-rank test. Cox proportional hazard models were then constructed to adjust for potentially confounding variables. PYY was
entered as a continuous variable into these models. The proportional hazards assumption was verified using Schoenfield residuals.
The SCFA from GCMS were analyzed using Agilent Mass Hunter Workstation Software for Quantitative Analysis. Peaks were in-
spected and corrected manually according to their retention times, including for IS. The area under the curve was obtained and
normalized with the respective intensity of the IS and calibration curves used. Results were expressed in concentration levels
with mM as the unit of measurement.
Processing of spectral data was conducted using Topspin v3.1 (Bruker, Karlsruhe Germany). Both SIMCA-P+ (Umetrics, Umea
Sweden) and MATLAB (The MathWorks Inc., Natick USA) were used to generate unsupervised (PCA: Principal Component Analysis)
and supervised (PLS: Projection to Latent Structures and O-PLS: Orthogonal Projection to Latent Structures) discriminant and
regression models and associated scores and loadings plots. Metabolite identification used statistical correlation spectroscopy
(STOCSY)68 and subset optimization by reference matching (STORM)69 to retrieve chemical shift patterns. Peak multiplicities
were determined using J-resolved spectra. These data were then compared with an in-house database and the HumanMetabolome
Database70 to identify metabolites.
16S rRNA data was processed as follows using the Mothur pipeline (Kozich et al., 2013) based on the online SOP accessed 14th
July 2017. Paired read sequences were combined to maximize the information available for phylogenetic classification, and those
with ambiguous bases or of the wrong length excluded. Similar paired sequences were clustered together as operational taxonomic
units (OTUs), and classified by comparison to reference databases including SILVA,71 Greengenes,72 and the Ribosomal Database
Project.73 Median read depth was 25141, ranging from 13724 to 36142. Data were subsampled to 13724 reads as the minimumCell Reports Medicine 2, 100280, May 18, 2021 e4
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dian). OTU data generated from the Mothur pipeline with corresponding taxonomy information was analyzed in the following ways.
Univariate comparisons based on associated metadata were undertaken in STAMP software (statistical analysis of taxonomic and
functional profiles) (Parks et al., 2014). Two group comparisons were conducted using two-sided White’s non-parametric t test, with
Benjamini-Hochberg false discovery rate (FDR) (Benjamini andHochberg, 1995) applied to correct for multiple testing. Multiple group
comparisons were conducted by the Kruskal-Wallis H-test, also using Benjamini-Hochberg FDR correction, with pairwise compar-
ison made by post hoc Tukey-Kramer test. For clarity, corrected p values which may be greater than 1.000 following multiple testing
correction have been capped at p = 1.000. Mothur scripts were used to calculate richness (Chao1 and Abundance-based Coverage
Estimator (ACE)) and alpha diversity statistics (Inverse Simpson Index and Inverse Shannon Index), which were then compared using
general statistical methods described above.
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